Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pulmonary hypertension phenotypes in patients with systemic sclerosis

Ashraful Haque, David G. Kiely, Gabor Kovacs, A.A. Roger Thompson, Robin Condliffe
European Respiratory Review 2021 30: 210053; DOI: 10.1183/16000617.0053-2021
Ashraful Haque
1Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
2Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
3Dept of Rheumatology, Royal Hallamshire Hospital, Sheffield, UK
6Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David G. Kiely
1Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
2Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David G. Kiely
Gabor Kovacs
4Medical University of Graz, Graz, Austria
5Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.A. Roger Thompson
1Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
2Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A.A. Roger Thompson
Robin Condliffe
1Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
2Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
6Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robin Condliffe
  • For correspondence: robin.condliffe@nhs.net
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Pulmonary hypertension (PH) commonly affects patients with systemic sclerosis (SSc) and is associated with significant morbidity and increased mortality. PH is a heterogenous condition and several different forms can be associated with SSc, including pulmonary arterial hypertension (PAH) resulting from a pulmonary arterial vasculopathy, PH due to left heart disease and PH due to interstitial lung disease. The incidence of pulmonary veno-occlusive disease is also increased. Accurate and early diagnosis to allow optimal treatment is, therefore, essential. Recent changes to diagnostic haemodynamic criteria at the 6th World Symposium on Pulmonary Hypertension have resulted in therapeutic uncertainty regarding patients with borderline pulmonary haemodynamics. Furthermore, the optimal pulmonary vascular resistance threshold for diagnosing PAH and the role of exercise in identifying early disease require further elucidation. In this article we review the epidemiology, diagnosis, outcomes and treatment of the spectrum of pulmonary vascular phenotypes associated with SSc.

Abstract

Different forms of pulmonary hypertension can be present in patients with systemic sclerosis. In this article we review the epidemiology, diagnosis, outcomes and treatment of the spectrum of pulmonary vascular phenotypes associated with systemic sclerosis. https://bit.ly/3xUwrVB

Introduction

Systemic sclerosis (SSc) is a multisystem autoimmune disorder characterised by inflammation, excessive collagen deposition and fibrosis [1]. Limited cutaneous systemic sclerosis (LcSSc) is characterised by skin thickening distal to the elbows and knees, with or without facial and neck involvement, and the frequent presence of anti-centromere antibodies, while diffuse cutaneous systemic sclerosis (DcSSc) is characterised by proximal skin thickening and a predominance of anti-topoisomerase 1 (Scl-70) antibodies and anti-RNA polymerase III antibodies [2]. Earlier and more frequent organ involvement occurs in DcSSc [3]. A small proportion of patients may present with clinical features of SSc in the absence of skin thickening (SSc sine scleroderma).

Pulmonary hypertension (PH) describes a heterogenous group of conditions defined by an elevated mean pulmonary arterial pressure (mPAP). Five classification groups are described: Group 1: pulmonary arterial hypertension (PAH); Group 2: PH due to left heart disease (PH-LHD); Group 3: PH due to lung diseases and/or hypoxia (PH-lung); Group 4: PH due to pulmonary artery obstructions; Group 5: PH with unclear and/or multifactorial mechanisms (figure 1) [5]. PAH is characterised by a progressive pulmonary arterial vasculopathy. Subsequent increased pulmonary vascular resistance (PVR) and pulmonary arterial pressure lead to increased right ventricular (RV) afterload with subsequent RV dysfunction, failure and premature death [6–8]. Despite the availability of specific therapies targeting three main pathways, PAH associated with SSc (SSc-PAH) is associated with a poor prognosis with 3-year survival of only 52% [9]. Patients with SSc may also develop other forms of PH (SSc-PH), especially PH-LHD (SSc-PH-LHD) and PH-lung (SSc-PH-lung). Pulmonary venous involvement may be relatively common in patients diagnosed with SSc-PAH while some patients may present with a predominant picture of pulmonary veno-occlusive disease (PVOD) [10–12]. Patients may also rarely present with group 4 disease, chronic thromboembolic pulmonary hypertension, as SSc is associated with an increased risk of venous thromboembolism [13].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Potential pulmonary hypertension (PH) classification groups associated with systemic sclerosis. Patients may develop a pulmonary arterial vasculopathy (group 1, pulmonary arterial hypertension), may develop PH due to left heart disease (group 2) or PH due to lung disease (group 3; most commonly interstitial lung disease, although the incidence of combined fibrosis and emphysema is also increased). The incidence of pulmonary veno-occlusive disease (group 1′) also appears to be increased in systemic sclerosis. Chronic thromboembolic PH (group 4) should be excluded while patients with a previous scleroderma renal crisis who progress to end-stage chronic kidney disease may develop group 5 disease. Reproduced and modified from [4] with permission from the publisher.

Diagnostic criteria with regard to the threshold of mPAP used to define the presence of PH, the use or non-use of a threshold for PVR to diagnose PAH, and the presence or absence of the entity of PH on exercise (PH-exercise) have changed over recent years (table 1). Furthermore, there are now a group of patients with elevated mPAP but normal PVR who are unclassifiable according to the most recent World Symposium on Pulmonary Hypertension (WSPH). Making the correct diagnosis regarding the form of SSc-PH is of critical importance in informing prognosis and guiding the most appropriate management strategy. Therefore, in this article we review the different PH phenotypes present in patients with SSc (table 2).

View this table:
  • View inline
  • View popup
TABLE 1

Haemodynamic diagnostic criteria of the six World Symposia on Pulmonary Hypertension (WSPH)

View this table:
  • View inline
  • View popup
TABLE 2

Systemic sclerosis (SSc)-pulmonary hypertension (PH) phenotypes

Methods

A PubMed systematic literature search was undertaken using the following search criteria:

((Systemic sclerosis) OR (Scleroderma) OR (Limited cutaneous systemic sclerosis) OR (Diffuse cutaneous systemic sclerosis)) AND ((Pulmonary hypertension) OR (Pulmonary arterial hypertension)) AND ((Exercise) OR (Borderline) OR (Interstitial lung disease) OR (ILD) OR (Diffusion capacity) OR (Left heart disease) OR (DLCO) OR (Transfer factor) OR (Phenotype)).

218 search results were all analysed for relevant information. Furthermore, a grey search of the manuscripts cited within these articles was undertaken together with the inclusion of key legacy papers.

Changing definitions of PH

The first WSPH was organised by the World Health Organization (WHO) in 1973 in response to a European epidemic of appetite suppressant-induced PH [14]. It defined PH by a mPAP at right heart catheterisation (RHC) >25 mmHg (table 1) [14]. This haemodynamic definition was derived from the recommendation of a previous WHO report on cor pulmonale, published in 1961 [22]. The diagnostic threshold of 25 mmHg would remain until the sixth WSPH in 2018 where it was proposed that the threshold be reduced to >20 mmHg [5]. This change in definition was suggested following a systematic review by Kovacs et al. [23] which demonstrated that the mean mPAP within the healthy population was 14.0±3.3 mmHg. In addition, Maron et al. [24] reviewed RHC data from 21 727 patients in the US Veterans healthcare system and observed increased mortality in patients with a mPAP 19–24 mmHg compared with <19 mmHg. Furthermore, a meta-analysis of 16 482 patients performed by Kolte et al. [25] also identified increased mortality in patients with mPAP >19 mmHg. It is interesting to note that although the 1961 report proposed a threshold of 25 mmHg, it also commented that the upper limit of normal for mPAP was 15 mmHg [22]. Furthermore, the first WSPH also stated that the mPAP at rest “never” exceeded 20 mmHg in healthy individuals [14]. The uncertain nature of patients with mPAP 21–24 mmHg had been recognised at the fourth and fifth World Symposia, but there were deemed to be insufficient data to introduce a formal definition of “borderline PH” [18, 19].

The effects of exercise on mPAP were discussed at the first WSPH, but were not included in diagnostic criteria [13]. By the third WSPH, a diagnostic threshold of mPAP >30 mmHg for the diagnosis of PH-exercise had been introduced [17, 26]. PH-exercise was, however, dropped from the diagnostic criteria in the fourth WSPH in 2008 as it was appreciated that mPAP may frequently increase >30 mmHg on exercise in normal individuals, especially those aged >50 years [17].

PVR was incorporated into the definition of PAH at the third WSPH using a threshold of >3 Wood Units (WU) [27]. Its inclusion in the definition aimed to prevent patients with flow-related increases in mPAP being diagnosed with PAH. Although it was temporarily absent from the fourth WSPH, it was reinserted into the diagnostic criteria for PAH at the fifth WSPH, albeit with the slight change of including patients with a PVR ≥3 WU (as opposed to >3 WU) [19].

Left atrial pressure, most commonly assessed by the pulmonary arterial wedge pressure (PAWP), was introduced in the third WSPH to differentiate between pre-capillary (PAWP ≤15 mmHg) and post-capillary PH (PAWP >15 mmHg) [16].

Summary

Haemodynamic criteria for different forms of PH have changed over recent decades. The most recent WSPH defines pre-capillary PH as mPAP >20 mmHg, PAWP ≤15 mmHg and PVR ≥3 WU.

SSc-PAH

Estimates of the prevalence of PAH within the SSc population range between 6.4% and 9% [27, 28]. The incidence of SSc-PAH in patients with LcSSc and DcSSc is 1.25 and 0.4 cases per 100 patient-years, respectively [29]. Meta-analysis involving 3818 patients with RHC-confirmed PH identified PAH as the most common form of PH seen in SSc, comprising 63% of RHC-confirmed cases [27]. There may, however, be ascertainment bias in these data due to patients with other forms of PH being less likely to undergo RHC. Historically, SSc-PAH was associated with a poor prognosis with a 3-year survival of 30% [30]. Mortality remains high despite the availability of PAH-specific therapy. Lefèvre et al. [9] observed 1- and 3-year survival rates of 81% and 52%, respectively, in a meta-analysis.

Several studies have demonstrated that, despite having less severe pulmonary haemodynamics, survival of patients with SSc-PAH is worse than with idiopathic PAH (IPAH) [31–37]. There are several possible explanations for this including differences in patient characteristics, the underlying pulmonary arterial vasculopathy, and the ability of the RV to compensate for increased afterload.

Patient characteristics

When compared with IPAH, patients with SSc-PAH are older with a lower coefficient for diffusing capacity of the lung for carbon monoxide (DLCO). In a multivariate analysis of 375 IPAH and SSc-PAH patients, Ramjug et al. [37] identified that higher age and lower DLCO were independent prognostic markers. The lower DLCO may reflect increased alveolar-capillary block due to overt or covert interstitial lung disease (ILD), reduced capillary blood volume related to the nature of the pulmonary vasculopathy or a component of PVOD. The multisystem nature of SSc, with involvement not only of the lungs and heart, but also the skin, gastrointestinal tract and kidneys, likely also impacts survival [38, 39].

Vasculopathy

Overbeek et al. [12] demonstrated intimal fibrosis in histological specimens from all eight patients they studied with SSc-PAH compared with only three out of 11 patients with IPAH. Plexiform lesions were much less common than in patients with IPAH. Similarly, Dorfmüller et al. [11] observed marked muscular artery intimal fibrosis in four out of four SSc-PAH patients in contrast with only four out of 29 patients with IPAH. In addition to differences in pulmonary arterial histology, there may also be an increased frequency of pulmonary venous lesions in SSc-PAH (see PVOD section) [40].

Right ventricle

Overbeek et al. [41] demonstrated poorer RV contractility in 13 patients with SSc-PAH compared with 17 IPAH patients. Similarly, Tedford et al. [42] observed worse RV contractility and coupling of RV contractility with afterload in seven SSc-PAH patients compared with five IPAH patients. Mathai et al. [43] found N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in 55 SSc-PAH patients to be significantly higher than in 43 IPAH patients, despite the IPAH group having more severe PH. Furthermore, although Overbeek et al. [41] found no difference in the extent of interstitial fibrosis in the RVs obtained at autopsy of five SSc-PAH and nine IPAH patients, there was an increased inflammatory myocardial infiltrate in the SSc-PAH group. Conversely, Hsu et al. [44] observed increased interstitial fibrosis in RV endomyocardial biopsies obtained from 11 SSc-PAH patients when compared with seven IPAH patients and six SSc patients without PH. Interestingly, when compared with healthy controls, sarcomere function (as assessed by the maximum calcium-activated force) was significantly lower in SSc-PAH but significantly higher in IPAH. Sarcomere function in SSc patients without PH was intermediate between the controls and SSc-PAH.

Medical therapy in SSc-PAH

Current therapies for PAH target three main pathways: nitric oxide, endothelin-1 and prostacyclin [45, 46]. A number of randomised controlled trials (RCTs) have published data on outcomes in patients with connective tissue disease (CTD), the majority of whom had SSc (table 3) [63]. With the exception of an unblinded RCT of epoprostenol, short-term monotherapy RCTs have tended to report lower response to therapy in patients with CTD associated PAH (CTD-PAH) [64, 65]. However, newer data from longer studies where the majority of patients have received combination therapy have challenged these findings [54, 56, 61].

View this table:
  • View inline
  • View popup
TABLE 3

Key randomised controlled trials and sub-group analyses in systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH)

Screening

Humbert et al. [66] observed milder haemodynamics and superior survival in a cohort of SSc patients identified in a screening programme as compared to presenting symptomatically. Although lead-time bias cannot be excluded as a cause of the superior survival, subsequent RCTs of PAH therapies have demonstrated larger treatment response of patients in functional class (FC) II compared with FC III [67]. There is, therefore, a good rationale for screening asymptomatic SSc patients to enable earlier treatment [68]. Coghlan et al. [69] compared the multi-modality 2-step DETECT algorithm with the European Respiratory Society/European Society of Cardiology (ERS/ESC) approach of echocardiography alone and observed sensitivity/specificity for identifying PAH (mPAP ≥25 mmHg and PAWP ≤15 mmHg) of 96%/48% and 71%/69%, respectively. The Australian Scleroderma Interest Group (ASIG) studied an approach using pulmonary function tests and NT-proBNP and reported sensitivity/specificity for identifying PAH of 94%/55% compared with 95%/32% for the ERS/ESC approach [70]. Hao et al. [71] compared all three approaches in 73 patients and observed that although the DETECT and ASIG approaches performed similarly, the ASIG algorithm reduced the need for RHC without missing any cases of PAH. A direct comparison of approaches is, however, difficult due to inclusion criteria used in different studies [72].

Although no difference in the incidence of PAH was identified when comparing the DETECT algorithm with an earlier approach involving symptoms, DLCO, NT-proBNP and echocardiography, Hoffmann-Vold et al. [73] observed that DETECT identified a significantly higher number of patients with mPAP 21–24 mmHg (31% versus 17%).

Summary​​​​​​​

Survival in SSc-PAH is worse than in IPAH which may be related to a number of factors including the multisystem nature of SSc and the capacity of the RV to accommodate increased afterload. Data from RCTs of combination therapies with combined morbidity/mortality end-points have, however, reported equivalent outcomes to those seen in IPAH. Patients with SSc-PAH should therefore receive timely dual and triple combination therapy. Asymptomatic SSc patients should be entered into screening programmes.

Impact of the sixth WSPH definition

Two studies investigating the effect of lowering the mPAP diagnostic threshold from ≥25 to >20 mmHg in patients with SSc have been published. Jaafar et al. [74] performed a retrospective, single centre analysis of 268 SSc patients who had undergone RHC [75]. Seven (5%) out of 131 SSc patients without PH according to the old definition were re-classified to either pre-capillary PH (PAH: n=1; PH-lung: n=3) or post-capillary PH (n=3) [74]. In those with mPAP 21–24 mmHg but without significant lung or left heart disease (n=28), a single patient (4% of the 21–24 mmHg group, 1% of the original no PH group) was reclassified as having PAH [74]. The authors also reanalysed 244 patients from the original DETECT cohort [69] and found that four (11%) out of 36 patients with mPAP 21–24 mmHg were reclassified as having PAH. Xanthouli et al. [76] subsequently studied 284 SSc patients, 146 (49%) of whom had a mPAP ≤20 mmHg and 55 (19%) had a mPAP of 21–24 mmHg. Only four patients (7% of the 21–24 mmHg group, 2% of the original no PH group) were reclassified with PAH [76]. The authors of both studies concluded that the new diagnostic criteria (with a change only to the mPAP threshold) had limited impact on the diagnosis of SSc-PAH.

Summary

Changes to the haemodynamic diagnosis of pre-capillary PH proposed at the sixth WSPH have only a modest effect on the number of patients diagnosed with SSc-PAH.

Elevated mPAP with PVR <3 WU

A proportion of SSc patients with normal PAWP who have preserved/mildly impaired cardiac outputs may have a mPAP >20 mmHg but a PVR <3 WU. For example, a SSc patient with a mPAP of 26 mmHg, PAWP 12 mmHg and a cardiac output of 5 L·min−1 has a PVR of (26–12)/5=2.8 WU and hence cannot be assigned a PH category. This occurrence will be made more common by the change in diagnostic threshold for mPAP from ≥25 mmHg to >20 mmHg. In the study by Jaafar et al. [74] discussed above, the use of a PVR threshold of 2 WU instead of 3 WU would have resulted in an increase from one to nine PAH re-diagnoses (32% of all patients with mPAP 21–24 mmHg). Similarly, in the study of Xanthouli et al. [76], the number of re-diagnoses would have increased from four to 28 (51% of patients with mPAP 21–24 mmHg). The use of a lower PVR threshold for the diagnosis of PAH is supported by several studies.

Xanthouli et al. [76] observed that the 28 patients with mPAP 21–24 mmHg but PVR ≥2 WU had lower 6-min walk distance (6MWD) and TAPSE (tricuspid annulus systolic excursion) and worse survival than patients with a PVR <2 WU. Kovacs et al. [77] found the mean PVR in 222 healthy volunteers in the literature to range from 0.77±0.3 WU in people aged <24 years to 1.13±0.5 WU in people aged ≥70 years. Maron et al. [78] retrieved RHC data from 40 082 patients in the US Veterans healthcare system (many with heart failure and/or COPD). In those patients with a mPAP ≥19 mmHg and PAWP ≤15 mmHg, the PVR threshold above which the hazard ratio for mortality increased was 2.2 WU. Ratwatte et al. [79] recently presented data on 82 patients (42 with CTD) with mPAP ≥25 mmHg, PAWP ≤15 mmHg but PVR <3 WU (median (interquartile range) 2.2 (1.9–2.7) WU) who were all treated with PAH-specific therapy. They found that this haemodynamic picture was associated with impaired function and reduced survival but was also associated with functional response to PAH-specific therapy [79].

SSc with mPAP 21–24 mmHg

Although the term “borderline pulmonary hypertension” was never adopted by international guidelines, several studies involving patients with mPAP 21–24 mmHg which were performed prior to changes in diagnostic thresholds in the sixth WSPH used this phrase (table 4). The majority of patients had a PVR <3 WU. These studies suggested that SSc with mPAP 21–24 mmHg is not a benign condition, being associated with a risk of haemodynamic progression and functional impairment [80–83, 85].

View this table:
  • View inline
  • View popup
TABLE 4

Key observational studies in systemic sclerosis (SSc) patients with mean pulmonary arterial pressure (mPAP) 21–24 mmHg

Summary

Patients with mPAP 21–24 mmHg are at risk of developing mPAP ≥25 mmHg during follow-up. When compared with either the previous approach (mPAP ≥25 mmHg and PVR ≥3 WU) or the sixth WSPH approach (mPAP >20 mmHg and PVR ≥3 WU), the use of an mPAP threshold of >20 mmHg and a PVR threshold of ≥2 WU is likely to be a superior approach for identifying SSc patients with pulmonary vascular disease.

SSc-PH-exercise

An excessive increase in mPAP following increased pulmonary blood flow on exercise may result from several factors including increased PVR due to pulmonary vascular remodelling, obstruction or destruction, reduced pulmonary arterial distensibility or transmission of increased left atrial pressure due to LHD [26, 86–88]. The first WSPH report stated that “some forms of pulmonary hypertension are latent and become apparent only when there is an increase in blood flow” [14]. It commented that mPAP rarely exceeds 30 mmHg on exercise, although it also subsequently stated that mPAP can increase to >30 mmHg during exercise in athletes or in the elderly [14]. As noted above, the diagnosis of exercise PH was introduced at the third WSPH in 2003 but, following a systematic review including data from 1187 healthy volunteers, it became apparent that the normal pressure response to exercise varies with age and exercise level and so defining an abnormal response by pressure alone was not possible [6]. The diagnosis of exercise PH was therefore removed at the fourth WSPH [17]. More recently, Herve et al. [89] studied 169 patients with resting mPAP ≤20 mmHg who underwent exercise-RHC. The addition of a total pulmonary resistance (TPR=mPAP/cardiac output) at maximal exercise of >3 WU to the previous criteria of mPAP >30 mmHg increased the specificity in identifying patients with pulmonary vascular disease or LHD from 0.77 to 1.0 [89]. The ERS statement on pulmonary haemodynamics on exercise consequently suggested that “exercise pulmonary hypertension may be defined as the presence of resting mPAP <25 mmHg and mPAP >30 mmHg during exercise with total pulmonary resistance >3 WU” [86]. The sixth WSPH, however, did not recommend the return of a formal exercise PH diagnosis, citing the difficulty in distinguishing exercise-related changes due to pulmonary vascular disease from those due to exercise-related increases in PAWP, especially given the practical difficulties in measuring PAWP on exercise and the uncertainty regarding normal values [5].

A number of studies have investigated the prevalence of SSc-PH-exercise with estimates ranging between 7% and 48%. In the majority of studies, however, exercise echocardiography rather than RHC was employed and so the true prevalence is not known. Condliffe et al. [90] identified 42 patients in the UK who met the third WSPH definition of SSc-PH-exercise and observed that 18% of patients developed resting SSc-PAH during a mean follow-up of 2.3 years. Stamm et al. [91] studied 28 SSc-PH-exercise patients and noted that mean survival (5.2 years) was similar to that of 17 patients with SSc-PH at rest (4.4 years). Zeder et al. [92] recently studied 80 SSc patients with a resting mPAP <25 mmHg and observed that TPR and PVR at exercise, but not at rest, predicted subsequent survival.

Summary

Exercise haemodynamics provide an opportunity to identify latent pulmonary vascular disease. At exercise, a mPAP >30 mmHg plus a TPR >3 WU identifies patients with pulmonary vascular or left heart disease. Technical difficulties in measuring PAWP and uncertainty regarding its normal value on exercise mean that distinguishing between these states is currently difficult.

Therapy in patients with mPAP 21–24 mmHg and SSc-PH-exercise

There are limited data on the effects of PAH-specific therapies in patients with mPAP 21–24 mmHg or SSc-PH-exercise. Kovacs et al. [93] studied 10 patients with mPAP 21–24 mmHg (PVR 2±0.8 WU) who underwent RHC at baseline, 1-year follow-up and after 6 months of treatment with bosentan. Pulmonary artery pressures worsened during the first year of observation but were then noted to stabilise during the 6 months of therapy while PVR worsened during the observation period but then significantly improved following therapy [93]. Saggar et al. [94] studied 12 patients with SSc-PH-exercise and noted significant improvements in both resting and exercise haemodyamics and 6MWD after 6 months of ambrisentan. Pan et al. [95] randomised 38 patients with mPAP 21–24 mmHg or SSc-PH-exercise to 6 months of ambrisentan or placebo. Although there was no significant effect on mPAP, ambrisentan was associated with significant improvements in PVR and cardiac index and a trend towards improved 6MWD.

Summary

Adequately powered RCTs of PAH therapies involving SSc patients with mPAP 21–24 mmHg and PH-exercise are required.

SSc-PVOD

Pulmonary veno-occlusive disease is a rare form of PH with significant involvement of pulmonary venules and veins [96]. The incidence of idiopathic disease is 0.5 per million per year [96, 97]. It can be autosomal recessively transmitted due to mutations in the EIF2AK4 gene [98]. It can also develop following exposure to alkylating chemotherapy agents or organic solvents [99, 100]. An association with SSc has also been recognised [11, 40, 101]. It is characterised histologically by occlusive venous intimal fibrous thickening [102]. Alveolar capillaries are often dilated due to downstream obstruction and angioproliferative lesions identical to those seen in pulmonary capillary haemangiomatosis are present in the majority of cases [103]. Pulmonary arterial involvement with intimal fibrosis and medial hypertrophy may also be present, although plexiform lesions are not seen. In the second WSPH, PVOD was classified as pulmonary venous hypertension (group 2.4). Since pulmonary haemodynamics are indistinguishable from those seen in PAH, PVOD was moved into group 1 disease (1.4.1) in the third WSPH [16]. A separate grouping of 1′ was devised for the fourth WSPH [17]. In recognition of the fact that PVOD can involve the pulmonary arterial, capillary and venous bed, the sixth WSPH defined a new classification (1.6): PAH with overt features of venous/capillaries (PVOD/PCH) involvement [5]. PVOD is characterised at lung function testing by significantly reduced DLCO and radiologically by septal lines, centrilobular ground-glass changes and mediastinal lymphadenopathy [10].

Günther et al. [10] reviewed high-resolution computed tomography (HRCT) images for 26 SSc patients with pre-capillary PH and reported septal lines in 89%, centrilobular ground-glass opacities in 46% and mediastinal lymphadenopathy in 58%. The presence of ≥2 radiographic signs was associated with subsequent pulmonary oedema following commencement of PAH-specific therapy. Dorfmüller et al. [11] compared tissue samples from eight patients with CTD-PAH to samples from 29 IPAH patients. Pulmonary vein and venule obstructive lesions were present in 75% of CTD-PAH patients but only 17% of the IPAH group [11]. In addition, 50% of the CTD patients had developed pulmonary oedema following commencement of PAH-specific therapy. Gupta et al. [104] recently reported features of PVOD in 15 out of 18 patients with SSc-PH-ILD who had undergone lung transplantation. It must be noted that the incidence of pulmonary oedema in these studies was significantly higher than is seen in routine clinical practice and that extrapolating the high incidences of PVOD observed in highly selected histopathological studies to the general SSc population is difficult. Nevertheless, PVOD should be considered if clinical deterioration occurs following commencement of PAH-specific therapy in patients with SSc. Survival in PVOD is poor and early transplant referral in suitable patients is recommended [105–107].

Summary

SSc is not only associated with the development of overt PVOD but it is likely that a proportion of patients with SSc-PAH have a PVOD component to their disease.

SSc-PH-LHD

Primary cardiac involvement in SSc may involve the myocardium, pericardium, conduction system and valves, with estimates of overall prevalence of clinically overt disease of 7–39% [108, 109]. Myocardial involvement may result from fibrosis or microvascular disease [110, 111] while LHD may also develop due to comorbidities such as systemic hypertension and coronary arterial disease. De Luca et al. [112] demonstrated greater levels of fibrosis at endomyocardial biopsy and a greater tendency of heart failure in 12 patients with SSc-associated myocarditis compared with 12 patients with idiopathic myocarditis and 10 patients with myocarditis associated with other forms of autoimmune disease. Cardiac magnetic resonance imaging (MRI) may demonstrate myocardial abnormalities even in the absence of overt cardiac dysfunction. For example, Poindron et al. [113] identified evidence of diffuse myocardial fibrosis using T1 mapping at cardiac MRI in 36 out of 72 unselected SSc patients, despite there being no difference in right or left ventricular volumes or ejection fraction between those with or without elevated T1. Ntusi et al. [114] demonstrated increased focal myocardial fibrosis (late gadolinium enhancement) and mycocardial oedema (using T2 mapping) in addition to higher T1 levels in 19 SSc patients compared with 20 controls. Although biventricular size and global ventricular function were preserved, impairment of peak systolic circumferential strain and peak diastolic strain rate, which correlated inversely with the level of diffuse myocardial fibrosis, were observed in the SSc group. Using echocardiography, Tennøe et al. [115] observed left ventricular diastolic dysfunction in 17% of 275 SSc patients at baseline and in 29% of patients after a median of 3.4 years follow-up. Allanore et al. [116] identified reduced left ventricular systolic function at echocardiography in 5.4% of 7073 patients in the European Scleroderma Trials and Research Group database. Patients without evidence of left ventricular dysfunction using standard echocardiography may have evidence of early “sub-clinical” disease using newer techniques. Guerra et al. [117] compared global longitudinal strain by performing speckle tracking echocardiography in 52 SSc patients without PH or known LHD and 52 age-matched controls. They observed a 2.5-fold increased risk of subclinical left ventricular systolic impairment and a 3.3-fold increased risk of subclinical right ventricular systolic impairment. D'Alto et al. [118] recently compared the response to fluid challenge in 25 SSc patients without PH and 25 healthy controls and concluded that SSc patients have an increased frequency of subclinical LV diastolic dysfunction.

Patients diagnosed with SSc-PAH may have co-existing LHD or occult PH-LHD. Fisher et al. [35] demonstrated LV diastolic dysfunction in 33% of patients who fulfilled haemodynamic diagnostic criteria for SSc-PAH but in only 10% of patients diagnosed with IPAH. Fox et al. [119] reclassified 11 (48%) out of 29 SSc-PAH patients with PH-LHD following a fluid challenge; mean left atrial dimension was higher in the reclassified patients. Robbins et al. [120] subsequently performed a fluid challenge in 207 patients (49% with an underlying CTD) who met haemodynamic diagnostic criteria for PAH. 46 patients (22%) were reclassified with PH-LHD; body mass index was higher and there was a higher frequency of systemic hypertension, diabetes and left atrial enlargement when compared with those patients who were not reclassified [120].

Differentiating between SSc-PAH and SSc-PH-LHD purely on the basis of haemodynamics may be problematic given the difficulties that can be experienced in obtaining reliable PAWP measurements. Lammi et al. [121] observed that 30% of 120 patients in the PHAROS registry with repeat RHC changed their PH classification group at follow-up. Patients’ pre-test probability for SSc-PAH or SSc-PH-LHD should therefore be assessed by considering risk factors (such as systemic hypertension, obesity and diabetes), ECG, left atrial size and markers of diastolic dysfunction on echocardiography [103]. It is recommended that PAWP is measured at end-expiration and that blood oxygen saturation in the wedged position should be checked to ensure that a reliable wedged position has been achieved [122].

PH-LHD may exist as a purely passive process whereby increased left ventricular filling pressures are transmitted backwards through the pulmonary circulation [21]. The fifth WSPH introduced the term isolated post-capillary PH (table 1) to describe the clinical state which is currently defined as mPAP >20 mmHg, PAWP >15 mmHg and PVR <3 WU (table 2) [21]. In some patients with PH-LHD, however, processes such as increased endothelin-1, inflammatory cellular infiltrate and reduced nitric oxide-induced vasodilation, can result in the development of an additional pulmonary vasculopathy [21]. These patients develop an increased PVR and are more likely to have features of PAH such as severely elevated mPAP and significant RV dilatation and dysfunction [123]. This state is termed combined pre- and post-capillary PH (CpcPH) and is defined as mPAP >20 mmHg, PAWP >15 mmHg and PVR ≥3 WU [21]. Patients with CpcPH typically also have an elevated transpulmonary gradient (TPG=mPAP–PAWP) >12 mmHg and a diastolic pulmonary artery pressure to PAWP gradient ≥7 mmHg.

20% of patients with SSc-PH in a large multicentre cohort were diagnosed with SSc-PH-LHD [27]. The commonest form of SSc-PH-LHD is that associated with heart failure with preserved ejection fraction (SSc-PH-HFpEF). Bourji et al. [124] compared 93 SSc-PAH patients with 24 SSc-PH-HFpEF patients. Patients with SSc-PH-HFpEF had higher body mass index, mPAP and PAWP and larger left atria but similar TPG to patients with SSc-PAH. Survival in SSc-HFpEF, when adjusted for haemodynamics, was inferior [124].

A number of RCTs have assessed the role of PAH-specific therapies in patients with PH-LHD [125–128]. Apart from a small study by Guazzi et al. [126] involving 44 patients treated with sildenafil which reported improvements in PVR and cardiopulmonary exercise test parameters, the published studies, to date, have failed to reach their primary end-points. Only one of these studies, the MELODY-1 trial, enrolled patients with CpcPH. There are a lack of data assessing response to PAH-specific therapies in SSc-PH-LHD.

Summary

The incidence of subclinical and overt LHD is increased in patients with SSc. A fluid challenge should be considered in patients with an increased pre-test probability of PH-LHD who have a PAWP of 13–15 mmHg. Treatment of underlying LHD should be optimised. Further data are needed regarding response to PAH therapies, especially in patients with SSc-CpcPH.

SSc-PH-ILD

Interstitial changes are visible on HRCT in up to 80% of SSc patients while clinically overt ILD is present in up to 40% [129]. The majority of SSc patients with ILD have nonspecific interstitial pneumonia with usual interstitial pneumonia being present in <10% of cases [130–132]. SSc-ILD is more common in DcSSc, in older patients at disease onset and in black and male patients [133–135]. Typically, ILD occurs within the first 3 years from diagnosis in DcSSc [135] while it develops later in LcSSc [136]. Goh et al. [137] observed poorer outcomes in SSc patients with extensive disease (defined as >20% lung involvement on HRCT or forced vital capacity (FVC) <70% in indeterminate cases) as opposed to limited disease. There are, however, no data validating the optimal threshold of lung involvement to differentiate SSc-PH-ILD from SSc-PAH. Some studies of SSc-PH-ILD have adopted the system of Goh et al. [137] while other studies have used a range of criteria including: the presence of any ILD [129, 138]; fibrosis extent >5% plus total lung capacity (TLC) or FVC <70% [139]; TLC <70% or moderate-severe fibrosis plus TLC 60–70% [140]; fibrosis extent >33% or FVC <60% [90]. Launay et al. [141] also used the system of Goh et al. [137] during their cluster analysis of 200 SSc patients with pre-capillary PH. In this study the presence of extensive ILD (cluster 2) was associated with significantly poorer survival while the presence or absence of limited ILD in the other three clusters did not appear to have prognostic importance. Antoniou et al. [142] identified combined fibrosis and emphysema in 12% of SSc patients with ILD including in 7.5% of life-long nonsmokers. Combined fibrosis and emphysema is associated with an increased risk of PH. Cottin et al. [143] demonstrated PH in five out of 10 SSc patients with combined fibrosis and emphysema.

Several studies have reported poorer survival in patients with SSc-PH-ILD compared with SSc-PAH [90, 138–140]. Meta-analysis in 2013 demonstrated 3-year survival of 56% in SSc-PAH and 35% in SSc-PH-ILD [9]. In a study of 39 SSc-PAH and 20 SSc-PH-ILD patients, Mathai et al. [140] found independent prognostic factors to be a diagnosis of SSc-PH-ILD, the presence of DcSSc, PVR index and DLCO. Similarly, Chauvelot et al. [138] observed that the presence of ILD, together with chronic kidney disease and a lower 6MWD, was an independent prognostic factor in a study involving 68 SSc-PH-ILD and 62 SSc-PAH patients. Response to PAH-specific therapies appears to be reduced in patients with SSc-PH-ILD. Le Pavec et al. [144] studied 70 patients with SSc-PH-ILD and demonstrated no improvements in WHO FC, 6MWD or pulmonary haemodynamics following institution of PAH therapies. Chauvelot et al. [138] observed poorer survival and lower frequency of improvement in WHO FC in SSc-PH-ILD compared with SSc-PAH patients.

Previous RCTs of PAH therapies in patients with non-CTD associated ILD±PH have either been negative [145] or associated with adverse outcomes [146, 147]. However, Waxman et al. [148] recently published the results of the INCREASE study which included 72 PH patients with CTD-associated ILD (CTD-PH-ILD) who were randomised to nebulised treprostinil or placebo for 16 weeks. Receiving treprostinil was associated with significant benefits in NT-proBNP and clinical deterioration (both p<0.05) while there was an improvement in 6MWD of 44 m in the CTD-ILD-PH patients (95% CI 10.77). There was, however, no effect of therapy on quality of life.

Summary

Survival in SSc-PH-ILD is worse than in SSc-PAH. Most observational studies have reported a lack of functional and haemodynamic response to PAH therapies in patients with SSc-PH-ILD. Further RCTs of PAH therapies specifically in SSc-PH-ILD are needed.

Conclusion

Several different and overlapping forms of PH can present in patients with SSc. Accurate and early diagnosis to allow optimal treatment is therefore essential. Therapeutic uncertainty exists for SSc-PAH patients with mild pulmonary haemodynamics, SSc-PH-LHD or SSc-PH-ILD and further studies in these groups are urgently needed. Furthermore, the optimal PVR threshold for diagnosing PAH and the role of exercise in identifying early disease requires further elucidation.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: A. Haque has nothing to disclose.

  • Conflict of interest: D.G. Kiely reports personal fees and non-financial support from Bayer, GSK, Janssen and MSD, outside the submitted work.

  • Conflict of interest: G. Kovacs reports personal fees and non-financial support from Bayer, GSK, Janssen, MSD, Boehringer Ingelheim, Novartis, Chiesi and Vitalaire, outside the submitted work.

  • Conflict of interest: A.A.R. Thompson reports personal fees and non-financial support from Janssen, outside the submitted work.

  • Conflict of interest: R. Condliffe reports personal fees and non-financial support from Bayer, GSK, Janssen and MSD, outside the submitted work.

  • Support statement: This review was funded by the British Heart Foundation (Intermediate Clinical Fellowship FS/18/13/3328). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received February 28, 2021.
  • Accepted May 4, 2021.
  • Copyright ©The authors 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Denton CP,
    2. Khanna D
    . Systemic sclerosis. Lancet 2017; 390: 1685–1699. doi:10.1016/S0140-6736(17)30933-9
    OpenUrlCrossRefPubMed
  2. ↵
    1. Stochmal A,
    2. Czuwara J,
    3. Trojanowska M, et al.
    Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol 2020; 58: 40–51. doi:10.1007/s12016-018-8718-8
    OpenUrlPubMed
  3. ↵
    1. Distler O,
    2. Allanore Y,
    3. Denton CP, et al.
    Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. Rheumatol 2018; 57: 813–817. doi:10.1093/rheumatology/kex504
    OpenUrlPubMed
  4. ↵
    1. Kiely DG,
    2. Elliot CA,
    3. Sabroe I, et al.
    Pulmonary hypertension: diagnosis and management. BMJ 2013; 346: f2028. doi:10.1136/bmj.f2028
    OpenUrlFREE Full Text
  5. ↵
    1. Simonneau G,
    2. Montani D,
    3. Celermajer DS, et al.
    Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. doi:10.1183/13993003.01913-2018
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Galiè N,
    2. Humbert M,
    3. Vachiery J-L, et al.
    2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67–119. doi:10.1093/eurheartj/ehv317
    OpenUrlCrossRefPubMed
    1. Campo A,
    2. Mathai SC,
    3. Le Pavec J, et al.
    Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252–260. doi:10.1164/rccm.200912-1820OC
    OpenUrlCrossRefPubMed
  7. ↵
    1. Van Der Bruggen CEE,
    2. Tedford RJ,
    3. Handoko ML, et al.
    RV pressure overload: from hypertrophy to failure. Cardiovasc Res 2017; 113: 1423–1432. doi:10.1093/cvr/cvx145
    OpenUrl
  8. ↵
    1. Lefèvre G,
    2. Dauchet L,
    3. Hachulla E, et al.
    Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 2013; 65: 2412–2423. doi:10.1002/art.38029
    OpenUrlCrossRefPubMed
  9. ↵
    1. Günther S,
    2. Jaïs X,
    3. Maitre S, et al.
    Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012; 64: 2995–3005. doi:10.1002/art.34501
    OpenUrlCrossRefPubMed
  10. ↵
    1. Dorfmüller P,
    2. Humbert M,
    3. Perros F, et al.
    Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893–902. doi:10.1016/j.humpath.2006.11.022
    OpenUrlCrossRefPubMed
  11. ↵
    1. Overbeek MJ,
    2. Vonk MC,
    3. Boonstra A, et al.
    Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2008; 34: 371–379. doi:10.1183/09031936.00106008
    OpenUrl
  12. ↵
    1. Schoenfeld SR,
    2. Choi HK,
    3. Sayre EC, et al.
    Risk of pulmonary embolism and deep venous thrombosis in systemic sclerosis: a general population-based study. Arthritis Care Res 2016; 68: 246–253. doi:10.1002/acr.22673
    OpenUrl
  13. ↵
    1. World Health Organization
    1. Hatano S,
    2. Strasser T
    , World Health Organization. Primary Pulmonary Hypertension: Report on a WHO meeting. Geneva, World Health Organization, 1975.
    1. Rich S
    . Primary Pulmonary Hypertension: Executive Summary from the World Symposium – Primary Pulmonary Hypertension 1998. http://www.wsphassociation.org/wp-content/uploads/2019/04/Primary-Pulmonary-Hypertension-Evian-1998.pdf
  14. ↵
    1. Barst RJ,
    2. McGoon M,
    3. Torbicki A, et al.
    Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: S40–S47. doi:10.1016/j.jacc.2004.02.032
    OpenUrlFREE Full Text
  15. ↵
    1. Badesch DB,
    2. Champion HC,
    3. Gomez Sanchez MA, et al.
    Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55–S66. doi:10.1016/j.jacc.2009.04.011
    OpenUrlFREE Full Text
  16. ↵
    1. Hoeper MM,
    2. Barberà JA,
    3. Channick RN, et al.
    Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54: S85–S96. doi:10.1016/j.jacc.2009.04.008
    OpenUrlFREE Full Text
  17. ↵
    1. Hoeper MM,
    2. Bogaard HJ,
    3. Condliffe R, et al.
    Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D42–D50. doi:10.1016/j.jacc.2013.10.032
    OpenUrlFREE Full Text
    1. Vachiéry JL,
    2. Tedford RJ,
    3. Rosenkranz S, et al.
    Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53: 1801897. doi 10.1183/13993003.01897-2018
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Vachiéry J-L,
    2. Adir Y,
    3. Barberà JA, et al.
    Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013; 62: D100–D108. doi:10.1016/j.jacc.2013.10.033
    OpenUrlFREE Full Text
  19. ↵
    Chronic cor pulmonale. Report of an expert committee. World Health Organ Tech Rep Ser 1961; 213: 35.
    OpenUrlPubMed
  20. ↵
    1. Kovacs G,
    2. Berghold A,
    3. Scheidl S, et al.
    Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888–894. doi:10.1183/09031936.00145608
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Maron BA,
    2. Hess E,
    3. Maddox TM, et al.
    Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 2016; 133: 1240–1248. doi:10.1161/CIRCULATIONAHA.115.020207
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Kolte D,
    2. Lakshmanan S,
    3. Jankowich MD, et al.
    Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J Am Heart Assoc 2018; 7: e009729. doi:10.1161/JAHA.118.009729
    OpenUrl
  23. ↵
    1. Condliffe R
    . Unmasking hidden disease: exercise pulmonary haemodynamics in systemic sclerosis. Eur Respir J 2017; 50: 1700885. doi:10.1183/13993003.00885-2017
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Avouac J,
    2. Airò P,
    3. Meune C, et al.
    Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290–2298. doi:10.3899/jrheum.100245
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Rubio-Rivas M,
    2. Homs NA,
    3. Cuartero D, et al.
    The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: systematic review and meta-analysis. Autoimmun Rev 2021; 20: 102713. doi:10.1016/j.autrev.2020.102713
    OpenUrl
  26. ↵
    1. Hachulla E,
    2. De Groote P,
    3. Gressin V, et al.
    The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831–1839. doi:10.1002/art.24525
    OpenUrlCrossRefPubMed
  27. ↵
    1. Koh ET,
    2. Lee P,
    3. Gladman DD, et al.
    Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989–993. doi:10.1093/rheumatology/35.10.989
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kawut SM,
    2. Taichman DB,
    3. Archer-Chicko CL, et al.
    Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344–350. doi:10.1378/chest.123.2.344
    OpenUrlCrossRefPubMed
    1. Chung L,
    2. Liu J,
    3. Parsons L, et al.
    Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383–1394. doi:10.1378/chest.10-0260
    OpenUrlCrossRefPubMed
    1. Clements PJ,
    2. Tan M,
    3. McLaughlin VV, et al.
    The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012; 71: 249–252. doi:10.1136/annrheumdis-2011-200265
    OpenUrlAbstract/FREE Full Text
    1. Hurdman J,
    2. Condliffe R,
    3. Elliot CA, et al.
    ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39: 945–955. doi:10.1183/09031936.00078411
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Fisher MR,
    2. Mathai SC,
    3. Champion HC, et al.
    Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043–3050. doi:10.1002/art.22069
    OpenUrlCrossRefPubMed
    1. Ramjug S,
    2. Hussain N,
    3. Hurdman J, et al.
    Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Respirology 2017; 22: 372–377. doi:10.1111/resp.12899
    OpenUrl
  30. ↵
    1. Ramjug S,
    2. Hussain N,
    3. Hurdman J, et al.
    Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes. Chest 2017; 152: 92–102. doi:10.1016/j.chest.2017.02.010
    OpenUrl
  31. ↵
    1. Coghlan JG,
    2. Schreiber B
    . An update on the evaluation and management of pulmonary hypertension in scleroderma. Curr Rheumatol Rep 2012; 14: 1–10. doi:10.1007/s11926-011-0226-2
    OpenUrlPubMed
  32. ↵
    1. Condliffe R,
    2. Howard LS
    . Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep 2015; 7: 6. doi:10.12703/P7-06
    OpenUrl
  33. ↵
    1. Dorfmüller P,
    2. Montani D,
    3. Humbert M
    . Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis associated pulmonary arterial hypertension. Eur Respir J 2010; 35: 6–8. doi:10.1183/09031936.00081009
    OpenUrlFREE Full Text
  34. ↵
    1. Overbeek MJ,
    2. Mouchaers KTB,
    3. Niessen HM, et al.
    Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension. Int J Rheumatol 2010; 2010: 604615. doi:10.1155/2010/604615
    OpenUrlPubMed
  35. ↵
    1. Tedford RJ,
    2. Mudd JO,
    3. Girgis RE, et al.
    Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6: 953–963. doi:10.1161/CIRCHEARTFAILURE.112.000008
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Mathai SC,
    2. Bueso M,
    3. Hummers LK, et al.
    Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35: 95–104. doi:10.1183/09031936.00074309
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Hsu S,
    2. Kokkonen-Simon KM,
    3. Kirk JA, et al.
    Right ventricular myofilament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension. Circulation 2018; 137: 2360–2370. doi:10.1161/CIRCULATIONAHA.117.033147
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Humbert M,
    2. Lau EMT,
    3. Montani D, et al.
    Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189–2208. doi:10.1161/CIRCULATIONAHA.114.006974
    OpenUrlFREE Full Text
  39. ↵
    1. Sommer N,
    2. Ghofrani HA,
    3. Pak O, et al.
    Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol 2021; 178: 6–30. doi:10.1111/bph.15016
    OpenUrl
    1. Galiè N,
    2. Ghofrani HA,
    3. Torbicki A, et al.
    Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157. doi:10.1056/NEJMoa050010
    OpenUrlCrossRefPubMed
    1. Badesch DB,
    2. Hill N,
    3. Burgess G, et al.
    Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34: 2417–2422.
    OpenUrlAbstract/FREE Full Text
    1. Galiè N,
    2. Brundage BH,
    3. Ghofrani HA, et al.
    Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903. doi:10.1161/CIRCULATIONAHA.108.839274
    OpenUrlAbstract/FREE Full Text
    1. Galiè N,
    2. Denton CP,
    3. Dardi F, et al.
    Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Int J Cardiol 2017; 235: 67–72. doi:10.1016/j.ijcard.2017.02.094
    OpenUrl
    1. Ghofrani HA,
    2. Galiè N,
    3. Grimminger F, et al.
    Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–340. doi:10.1056/NEJMoa1209655
    OpenUrlCrossRefPubMed
    1. Humbert M,
    2. Coghlan JG,
    3. Ghofrani HA, et al.
    Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76: 422–426. doi:10.1136/annrheumdis-2015-209087
    OpenUrlAbstract/FREE Full Text
    1. Rubin LJ,
    2. Badesch DB,
    3. Barst RJ, et al.
    Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903. doi:10.1056/NEJMoa012212
    OpenUrlCrossRefPubMed
  40. ↵
    1. Coghlan JG,
    2. Galiè N,
    3. Barberà JA, et al.
    Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2017; 76: 1219–1227. doi:10.1136/annrheumdis-2016-210236
    OpenUrlAbstract/FREE Full Text
    1. Galiè N,
    2. Barberà JA,
    3. Frost AE, et al.
    Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844. doi:10.1056/NEJMoa1413687
    OpenUrlCrossRefPubMed
  41. ↵
    1. Pulido T,
    2. Adzerikho I,
    3. Channick RN, et al.
    Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818. doi:10.1056/NEJMoa1213917
    OpenUrlCrossRefPubMed
    1. Barst RJ,
    2. Rubin LJ,
    3. Long WA
    . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301. doi:10.1056/NEJM199602013340504
    OpenUrlCrossRefPubMed
    1. Badesch DB,
    2. Tapson VF,
    3. McGoon MD, et al.
    Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 425–434. doi:10.7326/0003-4819-132-6-200003210-00002
    OpenUrlPubMed
    1. Simonneau G,
    2. Barst RJ,
    3. Galie N, et al.
    Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804. doi:10.1164/ajrccm.165.6.2106079
    OpenUrlCrossRefPubMed
    1. Oudiz RJ,
    2. Schilz RJ,
    3. Barst RJ, et al.
    Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 420–427. doi:10.1378/chest.126.2.420
    OpenUrlCrossRefPubMed
  42. ↵
    1. Gaine S,
    2. Chin K,
    3. Coghlan G, et al.
    Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2017; 50: 1602493. doi:10.1183/13993003.02493-2016
    OpenUrlAbstract/FREE Full Text
    1. Sitbon O,
    2. Channick R,
    3. Chin KM, et al.
    Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533. doi:10.1056/NEJMoa1503184
    OpenUrlCrossRefPubMed
  43. ↵
    1. Khanna D,
    2. Zhao C,
    3. Saggar R, et al.
    Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries. Br J Pharmacol 2021; 73: 837-847. doi:10.1002/art.41669
    OpenUrl
  44. ↵
    1. Rhee RL,
    2. Gabler NB,
    3. Sangani S, et al.
    Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1111–1117. doi:10.1164/rccm.201507-1456OC
    OpenUrlCrossRefPubMed
  45. ↵
    1. Badesch DB,
    2. McGoon MD,
    3. Barst RJ, et al.
    Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009; 36: 2244–2249. doi:10.3899/jrheum.081277
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Humbert M,
    2. Yaici A,
    3. De Groote P, et al.
    Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522–3530. doi:10.1002/art.30541
    OpenUrlCrossRefPubMed
  47. ↵
    1. White RJ,
    2. Vonk-Noordegraaf A,
    3. Rosenkranz S, et al.
    Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respir Res 2019; 20: 208. doi:10.1186/s12931-019-1180-1
    OpenUrl
  48. ↵
    1. Condliffe R,
    2. Kovacs G
    . Identifying early pulmonary arterial hypertension in patients with systemic sclerosis. Eur Respir J 2018; 51: 1800495. doi:10.1183/13993003.00495-2018
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Coghlan JG,
    2. Denton CP,
    3. Grünig E, et al.
    Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340–1349. doi:10.1136/annrheumdis-2013-203301
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Thakkar V,
    2. Stevens W,
    3. Prior D, et al.
    The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2013; 15: R193. doi:10.1186/ar4383
    OpenUrl
  51. ↵
    1. Hao Y,
    2. Thakkar V,
    3. Stevens W, et al.
    A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015; 17: 7. doi:10.1186/s13075-015-0517-5
    OpenUrl
  52. ↵
    1. Weatherald J,
    2. Montani D,
    3. Jevnikar M, et al.
    Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019; 28: 190023. doi:10.1183/16000617.0023-2019
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Hoffmann-Vold AM,
    2. Fretheim H,
    3. Midtvedt Ø, et al.
    Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. Rheumatol (Oxford) 2018; 57: 480–487.
    OpenUrl
  54. ↵
    1. Jaafar S,
    2. Visovatti S,
    3. Young A, et al.
    Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. Eur Respir J 2019; 54: 1900586. doi:10.1183/13993003.00586-2019
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Kovacs G,
    2. Olschewski H
    . Debating the new haemodynamic definition of pulmonary hypertension: much ado about nothing? Eur Respir J 2019; 54: 1901278. doi:10.1183/13993003.01278-2019
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Xanthouli P,
    2. Jordan S,
    3. Milde N, et al.
    Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis 2019; 79: 370–378. doi:10.1136/annrheumdis-2019-216476
    OpenUrl
  57. ↵
    1. Kovacs G,
    2. Olschewski A,
    3. Berghold A, et al.
    Pulmonary vascular resistances during exercise in normal subjects: A systematic review. Eur Respir J 2012; 39: 319–328. doi:10.1183/09031936.00008611
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Maron BA,
    2. Brittan EL,
    3. Hess E, et al.
    Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8: 873–884. doi:10.1016/S2213-2600(20)30317-9
    OpenUrl
  59. ↵
    1. Ratwatte S,
    2. Anderson J,
    3. Strange G, et al.
    Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. Eur Respir J 2020; 56: 1901654. doi:10.1183/13993003.01654-2019
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Bae S,
    2. Saggar R,
    3. Bolster MB, et al.
    Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335–1342. doi:10.1136/annrheumdis-2011-200546
    OpenUrlAbstract/FREE Full Text
    1. Valerio CJ,
    2. Schreiber BE,
    3. Handler CE, et al.
    Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 2013; 65: 1074–1084. doi:10.1002/art.37838
    OpenUrlCrossRefPubMed
    1. Visovatti SH,
    2. Distler O,
    3. Coghlan JG, et al.
    Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther 2014; 16: 493. doi:10.1186/s13075-014-0493-1
    OpenUrlCrossRefPubMed
  61. ↵
    1. Coghlan GJ,
    2. Wolf M,
    3. Distler O, et al.
    Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018; 51: 1701197. doi:10.1183/13993003.01197-2017
    OpenUrlAbstract/FREE Full Text
    1. Nagel C,
    2. Marra AM,
    3. Benjamin N, et al.
    Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary artery pressure. Arthritis Rheumatol 2019; 71: 805–816. doi:10.1002/art.40814
    OpenUrl
  62. ↵
    1. Kovacs G,
    2. Douschan P,
    3. Maron BA, et al.
    Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis? Eur J Heart Fail 2019; 21: 1057–1061. doi:10.1002/ejhf.1570
    OpenUrl
  63. ↵
    1. Kovacs G,
    2. Herve P,
    3. Barbera JA, et al.
    An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 2017; 50: 1601708. doi:10.1183/13993003.01708-2016
    OpenUrlAbstract/FREE Full Text
    1. Lau EMT,
    2. Chemla D,
    3. Godinas L, et al.
    Loss of vascular distensibility during exercise is an early hemodynamic marker of pulmonary vascular disease. Chest 2016; 149: 353–361. doi:10.1378/chest.15-0125
    OpenUrlCrossRefPubMed
  64. ↵
    1. Maor E,
    2. Grossman Y,
    3. Balmor RG, et al.
    Exercise haemodynamics may unmask the diagnosis of diastolic dysfunction among patients with pulmonary hypertension. Eur J Heart Fail 2015; 17: 151–158. doi:10.1002/ejhf.198
    OpenUrlCrossRefPubMed
  65. ↵
    1. Herve P,
    2. Lau EM,
    3. Sitbon O, et al.
    Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J 2015; 46: 728–737. doi:10.1183/09031936.00021915
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Condliffe R,
    2. Kiely DG,
    3. Peacock AJ, et al.
    Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151–157. doi:10.1164/rccm.200806-953OC
    OpenUrlCrossRefPubMed
  67. ↵
    1. Stamm A,
    2. Saxer S,
    3. Lichtblau M, et al.
    Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur Respir J 2016; 48: 1658–1667. doi:10.1183/13993003.00990-2016
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Zeder K,
    2. Avian A,
    3. Bachmaier G, et al.
    Exercise pulmonary resistances predict long-term survival in systemic sclerosis. Chest 2021; 159: 781–790. doi:10.1016/j.chest.2020.08.2110
    OpenUrl
  69. ↵
    1. Kovacs G,
    2. Maier R,
    3. Aberer E, et al.
    Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012; 64: 1257–1262. doi:10.1002/art.33460
    OpenUrlCrossRefPubMed
  70. ↵
    1. Saggar R,
    2. Khanna D,
    3. Shapiro S, et al.
    Effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study. Arthritis Rheum 2012; 64: 4072–4077. doi:10.1002/art.34614
    OpenUrlCrossRefPubMed
  71. ↵
    1. Pan Z,
    2. Marra AM,
    3. Benjamin N, et al.
    Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther 2019; 21: 217. doi:10.1186/s13075-019-1981-0
    OpenUrl
  72. ↵
    1. Montani D,
    2. Lau EM,
    3. Dorfmüller P, et al.
    Pulmonary veno-occlusive disease. Eur Respir J 2016; 47: 1518–1534. doi:10.1183/13993003.00026-2016
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Montani D,
    2. Price LC,
    3. Dorfmuller P, et al.
    Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189–200. doi:10.1183/09031936.00090608
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Eyries M,
    2. Montani D,
    3. Girerd B, et al.
    EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46: 65–69. doi:10.1038/ng.2844
    OpenUrlCrossRefPubMed
  75. ↵
    1. Perros F,
    2. Günther S,
    3. Ranchoux B, et al.
    Mitomycin-induced pulmonary veno-occlusive disease: evidence from human disease and animal models. Circulation 2015; 132: 834–847. doi:10.1161/CIRCULATIONAHA.115.014207
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. Montani D,
    2. Lau EM,
    3. Descatha A, et al.
    Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir J 2015; 46: 1721–1731. doi:10.1183/13993003.00814-2015
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Johnson SR,
    2. Patsios D,
    3. Hwang DM, et al.
    Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 2006; 33: 2347–2350.
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Pietra GG,
    2. Capron F,
    3. Stewart S, et al.
    Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 16: S25–S32. doi:10.1016/j.jacc.2004.02.033
    OpenUrl
  79. ↵
    1. Lantuéjoul S,
    2. Sheppard MN,
    3. Corrin B, et al.
    Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30: 850–857. doi:10.1097/01.pas.0000209834.69972.e5
    OpenUrlCrossRefPubMed
  80. ↵
    1. Gupta S,
    2. Gupta A,
    3. Rehman S, et al.
    Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation. ERJ Open Res 2019; 5: 00168-2018. doi:10.1183/23120541.00168-2018
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Holcomb B Jr,
    2. Lloyd J,
    3. Johnson E, et al.
    Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118: 1671–1679.
    OpenUrlCrossRefPubMed
    1. Montani D,
    2. Achouh L,
    3. Dorfmüller P, et al.
    Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87: 220–233. doi:10.1097/MD.0b013e31818193bb
    OpenUrlCrossRefPubMed
  82. ↵
    1. Hadinnapola C,
    2. Bleda M,
    3. Haimel M, et al.
    Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136: 2022–2033. doi:10.1161/CIRCULATIONAHA.117.028351
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Bissell LA,
    2. Md Yusof MY,
    3. Buch MH
    . Primary myocardial disease in scleroderma – a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. Rheumatol (Oxford) 2017; 56: 882–895.
    OpenUrlPubMed
  84. ↵
    1. Fernández-Codina A,
    2. Simeón-Aznar CP,
    3. Pinal-Fernandez I, et al.
    Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival. Rheumatol Int 2017; 37: 177. doi:10.1007/s00296-016-3470-y
    OpenUrl
  85. ↵
    1. Bulkley BH,
    2. Ridolfi RL,
    3. Salyer WR, et al.
    Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976; 53: 483–490. doi:10.1161/01.CIR.53.3.483
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Mizuno R,
    2. Fujimoto S,
    3. Saito Y, et al.
    Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study. Eur J Heart Fail 2010; 12: 268–275. doi:10.1093/eurjhf/hfp198
    OpenUrlCrossRefPubMed
  87. ↵
    1. De Luca G,
    2. Campochiaro C,
    3. De Santis M, et al.
    Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatol (Oxford) 2020; 59: 2523–2533.
    OpenUrl
  88. ↵
    1. Poindron V,
    2. Chatelus E,
    3. Canuet M, et al.
    T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. Semin Arthritis Rheum 2020; 50: 128–134. doi:10.1016/j.semarthrit.2019.06.013
    OpenUrlPubMed
  89. ↵
    1. Ntusi NA,
    2. Piechnik SK,
    3. Francis JM, et al.
    Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson 2014; 16: 21. doi 10.1186/1532-429x-16-21
    OpenUrlCrossRefPubMed
  90. ↵
    1. Tennøe AH,
    2. Murbræch K,
    3. Andreassen JC, et al.
    Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. J Am Coll Cardiol 2018; 72: 1804–1813. doi:10.1016/j.jacc.2018.07.068
    OpenUrlFREE Full Text
  91. ↵
    1. Allanore Y,
    2. Meune C,
    3. Vonk MC, et al.
    Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 218–221. doi:10.1136/ard.2008.103382
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. Guerra F,
    2. Stronati G,
    3. Fischietti C, et al.
    Global longitudinal strain measured by speckle tracking identifies subclinical heart involvement in patients with systemic sclerosis. Eur J Prev Cardiol 2018; 25: 1598–1606. doi:10.1177/2047487318786315
    OpenUrlCrossRef
  93. ↵
    1. D'Alto M,
    2. Romeo E,
    3. Argiento P, et al.
    Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. Pulm Circ 2019; 9: 2045894018816089.doi 10.1177/2045894018816089
  94. ↵
    1. Fox BD,
    2. Shimony A,
    3. Langleben D, et al.
    High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013; 42: 1083–1091. doi:10.1183/09031936.00091212
    OpenUrlAbstract/FREE Full Text
  95. ↵
    1. Robbins IM,
    2. Hemnes AR,
    3. Pugh ME, et al.
    High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014; 7: 116–122. doi:10.1161/CIRCHEARTFAILURE.113.000468
    OpenUrlAbstract/FREE Full Text
  96. ↵
    1. Lammi MR,
    2. Saketkoo LA,
    3. Gordon JK, et al.
    Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort. Pulm Circ 2018; 8: 2045893218757404. doi:10.1177/2045893218757404
    OpenUrl
  97. ↵
    1. Bonno EL,
    2. Viray MC,
    3. Jackson GR, et al.
    Modern right heart catheterization: beyond simple hemodynamics. Adv Pulm Hypertens 2020: 19: 6–15. doi:10.21693/1933-088X-19.1.6
    OpenUrl
  98. ↵
    1. Rosenkranz S,
    2. Gibbs JSR,
    3. Wachter R, et al.
    Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37: 942–954. doi:10.1093/eurheartj/ehv512
    OpenUrlCrossRefPubMed
  99. ↵
    1. Bourji KI,
    2. Kelemen BW,
    3. Mathai SC, et al.
    Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. Pulm Circ 2017; 7: 409–420. doi:10.1177/2045893217700438
    OpenUrlPubMed
  100. ↵
    1. Hoendermis ES,
    2. Liu LCY,
    3. Hummel YM, et al.
    Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015; 36: 2565–2573. doi:10.1093/eurheartj/ehv336
    OpenUrlCrossRefPubMed
  101. ↵
    1. Guazzi M,
    2. Vicenzi M,
    3. Arena R, et al.
    Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124: 164–174. doi:10.1161/CIRCULATIONAHA.110.983866
    OpenUrlAbstract/FREE Full Text
    1. Bonderman D,
    2. Ghio S,
    3. Felix SB, et al.
    Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128: 502–511. doi:10.1161/CIRCULATIONAHA.113.001458
    OpenUrlAbstract/FREE Full Text
  102. ↵
    1. Vachiéry J-L,
    2. Delcroix M,
    3. Al-Hiti H, et al.
    Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018; 51: 1701886. doi:10.1183/13993003.01886-2017
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Young A,
    2. Vummidi D,
    3. Visovatti S, et al.
    Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis. Arthritis Rheumatol 2019; 71: 1339–1349. doi:10.1002/art.40862
    OpenUrl
  104. ↵
    1. Desai SR,
    2. Veeraraghavan S,
    3. Hansell DM, et al.
    CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232: 560–567. doi:10.1148/radiol.2322031223
    OpenUrlCrossRefPubMed
    1. Okamoto M,
    2. Fujimoto K,
    3. Sadohara J, et al.
    A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. Respir Investig 2016; 54: 445–453. doi:10.1016/j.resinv.2016.05.004
    OpenUrl
  105. ↵
    1. Daimon T,
    2. Johkoh T,
    3. Honda O, et al.
    Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types. Intern Med 2009; 48: 753–761. doi:10.2169/internalmedicine.48.1714
    OpenUrlPubMed
  106. ↵
    1. Jung E,
    2. Suh CH,
    3. Kim HA, et al.
    Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch Rheumatol 2018; 33: 322–327. doi:10.5606/ArchRheumatol.2018.6630
    OpenUrl
    1. Mayes MD,
    2. Lacey JV,
    3. Beebe-Dimmer J, et al.
    Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246–2255. doi:10.1002/art.11073
    OpenUrlCrossRefPubMed
  107. ↵
    1. Nihtyanova SI,
    2. Schreiber BE,
    3. Ong VH, et al.
    Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625–1635. doi:10.1002/art.38390
    OpenUrl
  108. ↵
    1. Asano Y,
    2. Ihn H,
    3. Yamane K, et al.
    The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 204–210. doi:10.1046/j.1523-1747.2003.12028.x
    OpenUrlPubMed
  109. ↵
    1. Goh NSL,
    2. Desai SR,
    3. Veeraraghavan S, et al.
    Interstitial lung disease in systemic sclerosis a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248–1254. doi:10.1164/rccm.200706-877OC
    OpenUrlCrossRefPubMed
  110. ↵
    1. Chauvelot L,
    2. Gamondes D,
    3. Berthiller J, et al.
    Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease. Arthritis Rheumatol 2021; 73: 295–304. doi:10.1002/art.41512
    OpenUrl
  111. ↵
    1. Launay D,
    2. Humbert M,
    3. Berezne A, et al.
    Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140: 1016–1024. doi:10.1378/chest.10-2473
    OpenUrlCrossRefPubMed
  112. ↵
    1. Mathai SC,
    2. Hummers LK,
    3. Champion HC, et al.
    Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569–577. doi:10.1002/art.24267
    OpenUrlCrossRefPubMed
  113. ↵
    1. Launay D,
    2. Montani D,
    3. Hassoun PM, et al.
    Clinical phenotypes and survival of precapillary pulmonary hypertension in systemic sclerosis. PLoS One 2018; 13: e0197112. doi10.1371/journal.pone.0197112
    OpenUrl
  114. ↵
    1. Antoniou KM,
    2. Margaritopoulos GA,
    3. Goh NS, et al.
    Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheumatol 2016; 68: 1004–1012. doi:10.1002/art.39528
    OpenUrl
  115. ↵
    1. Cottin V,
    2. Nunes H,
    3. Brillet PY, et al.
    Combined pulmonary fibrosis and emphysema: a distinct under recognised entity. Eur Respir J 2005; 26: 586–593. doi:10.1183/09031936.05.00021005
    OpenUrlAbstract/FREE Full Text
  116. ↵
    1. Le Pavec J,
    2. Girgis RE,
    3. Lechtzin N, et al.
    Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63: 2456–2464. doi:10.1002/art.30423
    OpenUrlCrossRefPubMed
  117. ↵
    1. Corte TJ,
    2. Keir GJ,
    3. Dimopoulos K, et al.
    Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014; 190: 208–217. doi:10.1164/rccm.201403-0446OC
    OpenUrlCrossRefPubMed
  118. ↵
    1. Raghu G,
    2. Behr J,
    3. Brown KK, et al.
    Treatment of idiopathic pulmonary fibrosis with Ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641–649. doi:10.7326/0003-4819-158-9-201305070-00003
    OpenUrlCrossRefPubMed
  119. ↵
    1. Nathan SD,
    2. Behr J,
    3. Collard HR, et al.
    Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019; 7: 780–790. doi:10.1016/S2213-2600(19)30250-4
    OpenUrl
  120. ↵
    1. Waxman A,
    2. Restrepo-Jaramillo R,
    3. Thenappan T, et al.
    Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384: 325–334. doi:10.1056/NEJMoa2008470
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 30 Issue 161 Table of Contents
European Respiratory Review: 30 (161)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary hypertension phenotypes in patients with systemic sclerosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary hypertension phenotypes in patients with systemic sclerosis
Ashraful Haque, David G. Kiely, Gabor Kovacs, A.A. Roger Thompson, Robin Condliffe
European Respiratory Review Sep 2021, 30 (161) 210053; DOI: 10.1183/16000617.0053-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary hypertension phenotypes in patients with systemic sclerosis
Ashraful Haque, David G. Kiely, Gabor Kovacs, A.A. Roger Thompson, Robin Condliffe
European Respiratory Review Sep 2021, 30 (161) 210053; DOI: 10.1183/16000617.0053-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Changing definitions of PH
    • SSc-PAH
    • Impact of the sixth WSPH definition
    • Elevated mPAP with PVR <3 WU
    • SSc-PH-exercise
    • Therapy in patients with mPAP 21–24 mmHg and SSc-PH-exercise
    • SSc-PVOD
    • SSc-PH-LHD
    • SSc-PH-ILD
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Role of air pollutants in airway epithelial barrier dysfunction
  • E-cigarettes and nicotine abstinence
  • Lung imaging in cystic fibrosis
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society